WO2008111632A1 - Agoniste de récepteur de glucocorticoïde constitué d'un dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine - Google Patents
Agoniste de récepteur de glucocorticoïde constitué d'un dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine Download PDFInfo
- Publication number
- WO2008111632A1 WO2008111632A1 PCT/JP2008/054568 JP2008054568W WO2008111632A1 WO 2008111632 A1 WO2008111632 A1 WO 2008111632A1 JP 2008054568 W JP2008054568 W JP 2008054568W WO 2008111632 A1 WO2008111632 A1 WO 2008111632A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor agonist
- glucocorticoid receptor
- trimethyl
- phenyl
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Abstract
L'invention concerne un agoniste de récepteur de glucocorticoïde constitué d'un dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine. Une nouvelle activité pharmacologique de l'agoniste est également décrite. Un agoniste de récepteur de glucocorticoïde constitué d'un composé représenté par la formule (1) ci-dessous ou d'un sel de celui-ci, est décrit spécifiquement. [dans la formule ci-dessous, R1 représente un groupe représenté par la formule générale (2a), (3a), (4a) ou (5a); R2 et R3 peuvent être identiques ou différents, et peuvent représenter un atome d'hydrogène, un atome d'halogène, un groupe alkyle inférieur ou similaire; R4 représente un groupe alkyle inférieur; R5, R6, R7 et R8 représentent un atome d'halogène, un groupe alkyle inférieur, un groupe alcényle inférieur, un groupe alcoxy inférieur ou similaire, et m, n, p et q représentent 0, 1 ou 2.]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-063010 | 2007-03-13 | ||
JP2007063010 | 2007-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008111632A1 true WO2008111632A1 (fr) | 2008-09-18 |
Family
ID=39759563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/054568 WO2008111632A1 (fr) | 2007-03-13 | 2008-03-13 | Agoniste de récepteur de glucocorticoïde constitué d'un dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008255112A (fr) |
WO (1) | WO2008111632A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2085388A1 (fr) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur à substitution phénylamino et un groupe phényle dans lequel est introduit un ester en tant que substituants |
WO2009139361A1 (fr) * | 2008-05-12 | 2009-11-19 | 参天製薬株式会社 | Agoniste des récepteurs de glucocorticoïdes composé de dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine ayant un groupe oxy substitué |
WO2010029986A1 (fr) * | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | Agoniste de récepteur de glucocorticoïde comprenant un nouveau dérivé de 1,2,3,4-tétrahydroquinoxaline contenant un groupe phényle ayant une structure d’ester d’acide sulfonique introduite dans celui-ci en tant que substituant |
US8017775B2 (en) | 2005-09-14 | 2011-09-13 | Santen Pharmaceutical Co., Ltd. | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
US8193187B2 (en) | 2007-05-29 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity |
WO2013108921A1 (fr) * | 2012-01-20 | 2013-07-25 | 参天製薬株式会社 | Procédé industriel de préparation d'un dérivé de 1,2-dihydroquinoline ou d'un sel de celui-ci, et intermédiaire servant à sa préparation |
US8551991B2 (en) | 2006-03-14 | 2013-10-08 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
WO2018230713A1 (fr) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Composés ayant une activité inhibitrice de caspase, agent pharmaceutique les contenant pour le traitement ou la prévention des symptômes, troubles ou maladies de l'endothélium cornéen, et application dudit agent pharmaceutique |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510840A (ja) * | 1994-12-22 | 1998-10-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | ステロイド受容体モジュレーター化合物および方法 |
JP2006504678A (ja) * | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
WO2006019716A1 (fr) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Composés modulateurs de récepteurs intracellulaires et procédés de production et d'utilisation de ceux-ci |
WO2007032556A1 (fr) * | 2005-09-14 | 2007-03-22 | Santen Pharmaceutical Co., Ltd. | Nouveau dérivé de 1-2-dihydroquinoline présentant une activité de liaison aux récepteurs glucocorticoïdes |
-
2008
- 2008-03-13 JP JP2008063419A patent/JP2008255112A/ja not_active Withdrawn
- 2008-03-13 WO PCT/JP2008/054568 patent/WO2008111632A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510840A (ja) * | 1994-12-22 | 1998-10-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | ステロイド受容体モジュレーター化合物および方法 |
JP2006504678A (ja) * | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
WO2006019716A1 (fr) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Composés modulateurs de récepteurs intracellulaires et procédés de production et d'utilisation de ceux-ci |
WO2007032556A1 (fr) * | 2005-09-14 | 2007-03-22 | Santen Pharmaceutical Co., Ltd. | Nouveau dérivé de 1-2-dihydroquinoline présentant une activité de liaison aux récepteurs glucocorticoïdes |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420635B2 (en) | 2005-09-14 | 2013-04-16 | Santen Pharmaceutical Co., Ltd. | Method for preventing or treating a glucocorticoid receptor-related disease |
US8017775B2 (en) | 2005-09-14 | 2011-09-13 | Santen Pharmaceutical Co., Ltd. | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
US8551991B2 (en) | 2006-03-14 | 2013-10-08 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
US8975256B2 (en) | 2006-03-14 | 2015-03-10 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity |
US8008497B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
EP2085387A4 (fr) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur phénylchalcogéno substitué et un groupe phényle introduit par un ester en tant que substituants |
EP2085388A4 (fr) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur à substitution phénylamino et un groupe phényle dans lequel est introduit un ester en tant que substituants |
EP2085389A4 (fr) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Nouveau dérivé de 1,2-dihydroquinoline comprenant en tant que substituants un groupe alkyle inférieur-carbonyloxy (à substitution phényle ou substitution hétérocyclique) et un groupe phényle lié par un ester |
US8580784B2 (en) | 2006-11-14 | 2013-11-12 | Santen Pharmaceutical Co., Ltd. | Method for treating a disease related to the glucocorticoid receptor |
US8008496B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
US8008498B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
EP2085389A1 (fr) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Nouveau dérivé de 1,2-dihydroquinoline comprenant en tant que substituants un groupe alkyle inférieur-carbonyloxy (à substitution phényle ou substitution hétérocyclique) et un groupe phényle lié par un ester |
EP2085388A1 (fr) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur à substitution phénylamino et un groupe phényle dans lequel est introduit un ester en tant que substituants |
EP2085387A1 (fr) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur phénylchalcogéno substitué et un groupe phényle introduit par un ester en tant que substituants |
US8563551B2 (en) | 2006-11-14 | 2013-10-22 | Santen Pharmaceutical Co., Ltd. | Method for preventing or treating a disease related to the glucocorticoid receptor |
US8440660B2 (en) | 2006-11-14 | 2013-05-14 | Santen Pharmaceutical Co., Ltd. | Method for treating a disease related to the glucocorticoid receptor |
US8569493B2 (en) | 2007-05-29 | 2013-10-29 | Santen Pharmaceutical Co., Ltd. | Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound |
US8193187B2 (en) | 2007-05-29 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity |
US8426406B2 (en) | 2008-05-12 | 2013-04-23 | Santen Pharmaceutical Co., Ltd. | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group |
EA019091B1 (ru) * | 2008-05-12 | 2014-01-30 | Сантен Фармасьютикал Ко., Лтд. | Агонист глюкокортикоидного рецептора, включающий 2,2,4-триметил-6-фенил-1,2-дигидрохинолиновые производные, содержащие замещенную оксигруппу |
WO2009139361A1 (fr) * | 2008-05-12 | 2009-11-19 | 参天製薬株式会社 | Agoniste des récepteurs de glucocorticoïdes composé de dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine ayant un groupe oxy substitué |
EA018420B1 (ru) * | 2008-09-12 | 2013-07-30 | Сантен Фармасьютикал Ко., Лтд. | Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя |
WO2010029986A1 (fr) * | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | Agoniste de récepteur de glucocorticoïde comprenant un nouveau dérivé de 1,2,3,4-tétrahydroquinoxaline contenant un groupe phényle ayant une structure d’ester d’acide sulfonique introduite dans celui-ci en tant que substituant |
US8664221B2 (en) | 2008-09-12 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent |
JP2013166752A (ja) * | 2012-01-20 | 2013-08-29 | Santen Pharmaceut Co Ltd | 1,2−ジヒドロキノリン誘導体またはその塩の工業的製造方法およびその製造中間体 |
WO2013108921A1 (fr) * | 2012-01-20 | 2013-07-25 | 参天製薬株式会社 | Procédé industriel de préparation d'un dérivé de 1,2-dihydroquinoline ou d'un sel de celui-ci, et intermédiaire servant à sa préparation |
CN104136432A (zh) * | 2012-01-20 | 2014-11-05 | 参天制药株式会社 | 1,2-二氢喹啉衍生物或其盐的工业制备方法及其制备中间体 |
WO2018230713A1 (fr) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Composés ayant une activité inhibitrice de caspase, agent pharmaceutique les contenant pour le traitement ou la prévention des symptômes, troubles ou maladies de l'endothélium cornéen, et application dudit agent pharmaceutique |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2008255112A (ja) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008111632A1 (fr) | Agoniste de récepteur de glucocorticoïde constitué d'un dérivé de 2,2,4-triméthyl-6-phényl-1,2-dihydroquinoléine | |
WO2009035067A1 (fr) | Agonistes des récepteurs des glucocorticoïdes constitués de dérivés de la 1,3,3-triméthyle-7-phényle-3,4-dihydro-1h-quinoxaline-2-one | |
TW200606152A (en) | Piperidine compound and process for preparing the same | |
WO2008096829A1 (fr) | Composés tricycliques | |
WO2008051533A3 (fr) | Composés de benzimidazole | |
WO2009072621A1 (fr) | Composé dihydroazole substitué et agent antiparasitaire | |
MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
WO2008087933A1 (fr) | Nouveau dérivé d'indole ayant une activité inhibitrice sur la iκb kinase β | |
WO2009156861A3 (fr) | Dérivés de pyrimidone substitués | |
EP2085387A4 (fr) | Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur phénylchalcogéno substitué et un groupe phényle introduit par un ester en tant que substituants | |
WO2008140066A3 (fr) | Nouveaux composés | |
WO2008111239A1 (fr) | Agent antiélectrostatique et son utilisation | |
WO2009057784A1 (fr) | Composé hétérocyclique | |
WO2008111604A1 (fr) | Nouveau composé de pyrimidine ayant une structure de benzyl(hétérocycliqueméthyl)amine et produit pharmaceutique la contenant | |
WO2008093674A1 (fr) | Nouveau dérivé de thiadiazole ayant une activité inhibitrice de la kinase | |
EP1798227A4 (fr) | Agoniste du récepteur 5-ht3 de la sérotonine | |
TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
WO2009156864A3 (fr) | Dérivés pyrimidin-4-one à substitution alkyle | |
WO2005115984A3 (fr) | Composés bicycliques | |
WO2008136444A1 (fr) | Dérivé hétérocyclique fusionné | |
MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
WO2007147771A3 (fr) | Dérivés tétraline et indane et leurs utilisations | |
ATE396183T1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
WO2008114812A1 (fr) | Inhibiteur de jak | |
MX2010012303A (es) | Agonista de receptor de glucocorticoide compuesto de derivado de 2,2,4-trimetil-6-fenil-1,2-dihidroquinolina que tiene un grupo oxi sustituido. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08721981 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08721981 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |